AR049707A1 - Regimenes y kits de progestina ciclica - Google Patents

Regimenes y kits de progestina ciclica

Info

Publication number
AR049707A1
AR049707A1 ARP050102805A ARP050102805A AR049707A1 AR 049707 A1 AR049707 A1 AR 049707A1 AR P050102805 A ARP050102805 A AR P050102805A AR P050102805 A ARP050102805 A AR P050102805A AR 049707 A1 AR049707 A1 AR 049707A1
Authority
AR
Argentina
Prior art keywords
progestine
regimes
kits
cycle
administration
Prior art date
Application number
ARP050102805A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35064935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049707(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR049707A1 publication Critical patent/AR049707A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se provee un método de anticoncepcion que incluye la administracion de 21 a 27 días consecutivos de una progestina en ausencia de un estrogeno u otro compuesto esteroide, seguido de 1 a 7 días sin una cantidad efectiva de un agente activo. Se describe, además, un kit util desde el punto de vista farmacéutico para facilitar la administracion de este régimen.
ARP050102805A 2004-07-07 2005-07-06 Regimenes y kits de progestina ciclica AR049707A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58604504P 2004-07-07 2004-07-07

Publications (1)

Publication Number Publication Date
AR049707A1 true AR049707A1 (es) 2006-08-30

Family

ID=35064935

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102805A AR049707A1 (es) 2004-07-07 2005-07-06 Regimenes y kits de progestina ciclica

Country Status (14)

Country Link
US (3) US20060009428A1 (es)
EP (1) EP1773344A1 (es)
JP (2) JP5288796B2 (es)
CN (2) CN1980676A (es)
AR (1) AR049707A1 (es)
AU (1) AU2005269938A1 (es)
BR (1) BRPI0512991A (es)
CA (1) CA2571377C (es)
MX (1) MXPA06014579A (es)
PA (1) PA8638601A1 (es)
PE (1) PE20060378A1 (es)
SV (1) SV2006002165A (es)
TW (1) TW200603813A (es)
WO (1) WO2006014476A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
BRPI0512991A (pt) 2004-07-07 2008-04-22 Wyeth Corp uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
BRPI0610438A2 (pt) * 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição
TW200716129A (en) * 2005-04-28 2007-05-01 Wyeth Corp Micronized tanaproget, compositions, and methods of preparing the same
DE602006013114D1 (de) 2005-04-28 2010-05-06 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
HN2006020928A (es) * 2005-06-09 2011-02-16 Wyeth Corp "composiciones de tanaproget que contienen etinil estradiol"
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
AU2008341138A1 (en) * 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
WO2010042607A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc Transdermal delivery
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
CA2756222A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
EP2533799B8 (en) * 2010-02-08 2019-12-25 Shenzhen Evergreen Therapeutics Co., Ltd. Methods for the use of progestogen as a glucocorticoid sensitizer
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
EP2730284A1 (en) * 2012-11-12 2014-05-14 Naari AG Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN107982520A (zh) * 2017-12-25 2018-05-04 上海交通大学医学院附属第九人民医院 外源性MPA与hMG在制备动物模型药物中的应用
JP7115911B2 (ja) 2018-06-12 2022-08-09 矢崎エナジーシステム株式会社 電力ケーブルの絶縁劣化検出装置および絶縁劣化検出方法
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
EP0559240B1 (en) * 1987-09-24 2001-12-05 Jencap Research Limited Contraceptive packages containing oestrogen and progestin
EP0956024B1 (en) 1996-07-26 2004-07-21 Wyeth Monophasic oral contraceptive method and kit comprising a combination of progestin and estrogen
WO2001030355A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
WO1999051214A2 (en) * 1998-04-07 1999-10-14 Akzo Nobel N.V. Progestogen-only contraceptive kit
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
DE60038108T2 (de) * 1999-05-04 2009-02-12 Wyeth Cyclothiocarbamatderivate als progesteron-rezeptormodulatoren
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
CA2383650A1 (en) * 1999-08-31 2001-04-19 Jenapharm Gmbh & Co. Kg Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
KR20050013627A (ko) * 2002-06-25 2005-02-04 와이어쓰 Ｐｒ 조절제로서의 사이클로티오카바메이트 유도체 및피부 질환을 치료하기 위한 이의 용도
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
BRPI0512991A (pt) 2004-07-07 2008-04-22 Wyeth Corp uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
EP1773344A1 (en) 2007-04-18
CN1980676A (zh) 2007-06-13
AU2005269938A1 (en) 2006-02-09
US20100292198A1 (en) 2010-11-18
US20140094458A1 (en) 2014-04-03
CA2571377C (en) 2014-03-25
WO2006014476A1 (en) 2006-02-09
JP2008505909A (ja) 2008-02-28
JP5288796B2 (ja) 2013-09-11
PA8638601A1 (es) 2006-07-03
US8604027B2 (en) 2013-12-10
PE20060378A1 (es) 2006-06-02
TW200603813A (en) 2006-02-01
MXPA06014579A (es) 2007-03-01
CA2571377A1 (en) 2006-02-09
US20060009428A1 (en) 2006-01-12
CN104208067A (zh) 2014-12-17
SV2006002165A (es) 2006-05-09
BRPI0512991A (pt) 2008-04-22
JP2013040181A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
AR049707A1 (es) Regimenes y kits de progestina ciclica
GT200500186A (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
AR030737A1 (es) Metodo de anticoncepcion y forma de administracion del mismo
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
PE20070329A1 (es) Composiciones con estrogenos y metodos terapeuticos para su uso
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
RS51076B (sr) Stabilizovani superzasićeni tvrdi rastvori steroidnih lekova
PE20070208A1 (es) Anticoncepcion oral con trimegestona
NO20062945L (no) Forlenget anvendelseskombinasjon omfattende ostrogener og progestiner
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
DOP2006000241A (es) Composiciones farmacéuticas sólidas que contienen pregabalina
MA26843A1 (fr) NOUVELLES COMPOSITIONS ESTRO-PROGESTATIVES TOPIQUES à EFFET SYSTÉMIQUE
BRPI0505524A (pt) método passìvel de utilização com um poço subterráneo, sistema passìvel de utilização com um poço subterráneo, e ferramenta passìvel de utilização com um poço subterráneo
PE20070327A1 (es) Composicion que comprende una progestina y un estrogeno
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
ECSP055629A (es) COMPOSICIÓN QUE CONTIENE UN ESTEROIDE 11ß-HALOGENADO ANDRÓGENO Y UN GESTÁGENO ASÍ COMO UN CONTRACEPTIVO MASCULINO SOBRE LA BASE DE ESTAS COMPOSICIONES
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
CR8010A (es) Regimenes de contraceptivos transdermicos extendidos
AR046762A1 (es) Hormonas de administracion transdermica que no necesitan potenciadores de penetracion
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure